KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Research & Development: 2009-2024

Historic Research & Development for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $79.0 million.

  • Halozyme Therapeutics' Research & Development fell 6.54% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 12.40%. This contributed to the annual value of $79.0 million for FY2024, which is 3.52% up from last year.
  • As of FY2024, Halozyme Therapeutics' Research & Development stood at $79.0 million, which was up 3.52% from $76.4 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Research & Development high stood at $79.0 million for FY2024, and its period low was $34.2 million during FY2020.
  • Its 3-year average for Research & Development is $74.0 million, with a median of $76.4 million in 2023.
  • In the last 5 years, Halozyme Therapeutics' Research & Development plummeted by 75.69% in 2020 and then skyrocketed by 86.72% in 2022.
  • Halozyme Therapeutics' Research & Development (Yearly) stood at $34.2 million in 2020, then climbed by 4.19% to $35.7 million in 2021, then soared by 86.72% to $66.6 million in 2022, then climbed by 14.65% to $76.4 million in 2023, then rose by 3.52% to $79.0 million in 2024.